Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating
阿格斯将Bio-Techne的目标股价从90美元调整至95美元,维持买入评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册